Fredun Pharmaceuticals Limited (BOM:539730)

India flag India · Delayed Price · Currency is INR
701.50
+6.10 (0.88%)
At close: May 2, 2025
-25.03%
Market Cap 3.30B
Revenue (ttm) 4.06B
Net Income (ttm) 187.98M
Shares Out 4.70M
EPS (ttm) 40.35
PE Ratio 17.38
Forward PE n/a
Dividend 0.70 (0.10%)
Ex-Dividend Date n/a
Volume 1,716
Average Volume 4,374
Open 695.40
Previous Close 695.40
Day's Range 690.00 - 708.40
52-Week Range 635.00 - 1,024.00
Beta 0.85
RSI 55.14
Earnings Date May 16, 2025

About Fredun Pharmaceuticals

Fredun Pharmaceuticals Limited manufactures and sells pharmaceutical formulations, dietary/herbal supplements, nutraceuticals, and other healthcare products in India, Africa, Southeast Asia, CIS countries, and Latin America. The company offers allopathic formulations, including analgesics/NSAID, antacid/antiulcer, anthelmintic, anti-bacterial, anti-diabetic, anti-inflammatory, anti-malarial, anti-obesity, antacid, anthelmintic, antibacterial, analgesics, anti-diabetic, anti-inflammatory, anti-malarial, anti-obesity, anticoagulants, anticonvulsa... [Read more]

Industry Pharmaceutical Preparations
Founded 1987
Employees 256
Stock Exchange Bombay Stock Exchange
Ticker Symbol 539730
Full Company Profile

Financial Performance

In 2023, Fredun Pharmaceuticals's revenue was 3.48 billion, an increase of 26.75% compared to the previous year's 2.75 billion. Earnings were 156.23 million, an increase of 44.57%.

Financial Statements

News

Fredun Pharmaceuticals stock jumps 3% after company set to launch advanced functional foods plant

Fredun Pharmaceuticals Limited saw a 3% jump in its stock price following the announcement of its new cutting-edge functional foods manufacturing facility. Located in Palghar, Maharashtra, this state-...

5 months ago - Business Upturn